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Abstract Resistance of normal cells to tumour necrosis factor
related apoptosis inducing ligand (TRAIL) induced apoptosis is
believed to be mediated by expression of two decoy receptors.
Here we show that the expression and localisation of TRAIL
receptors (TRAIL-Rs) vary between different cells and that
resistance to TRAIL is mediated by different mechanisms. The
decoy receptor, TRAIL-R3, appeared important in protection of
endothelial cells, whereas lack of surface death receptor
expression and as yet unknown intracellular inhibitor(s) of
apoptosis downstream of caspase-3 may play a major role in
protection of melanocytes and fibroblasts from TRAIL induced
apoptosis, respectively. Differential subcellular location of decoy
receptors may be an important determinant of their effectiveness
in different types of normal cells. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
Key words: TNF related apoptosis inducing ligand; TNF
related apoptosis inducing ligand receptor; TNF related
apoptosis inducing ligand induced apoptosis; Normal cell
1. Introduction
Tumour necrosis factor (TNF) related apoptosis inducing
ligand (TRAIL) is a member of the TNF family which can
induce apoptosis in a wide range of transformed cell lines but
not normal cells [1,2]. TRAIL induces apoptosis by interac-
tion with two death domain containing receptors referred to
as TRAIL-R1/DR4 [3,4] and TRAIL-R2/DR5/TRICK 2 [5^
7]. Both of these receptors are type I transmembrane proteins
and their mRNAs were found to be widely expressed on nor-
mal tissues. The latter are believed to be protected from apo-
ptosis by two additional receptors, TRAIL-R3/DcR1/TRID/
LIT [8^11] and TRAIL-R4/DcR2/TRUNDD [12^14].
TRAIL-R3 is an extracellular glycosyl phosphatidylinositol
(GPI) linked protein without an intracellular domain [8^11].
TRAIL-R4, like TRAIL-R1 and -R2, is a type I transmem-
brane protein but contains a truncated cytoplasmic death do-
main [12^14]. TRAIL-R3 and -R4 were thus considered to
inhibit TRAIL induced apoptosis either by acting as decoy
receptors or by providing inhibitory signals such as activation
of the transcription factor NF-UB [14,15] which is known to
regulate several inhibitors of apoptosis (c-IAP1, c-IAP2 and
XIAP) [16,17]. In addition, the death receptors TRAIL-R1
and -R2 are also known to be able to activate NF-UB upon
ligation [3^7]. A ¢fth TRAIL-R, osteoprotegerin, exists pre-
dominantly in a secreted form and appears to inhibit TRAIL
induced apoptosis by competitive inhibition of TRAIL bind-
ing to the death receptors TRAIL-R1 and -R2 [18].
In studies on melanoma cell lines we have shown that
TRAIL induced apoptosis is determined largely by the level
of surface expression of the death receptors, particularly
TRAIL-R2 [19]. Expression of the decoy receptors appeared
to play very little role in determining their susceptibility to
TRAIL [19]. We also found that intracellular pools of TRAIL
receptors existed in most melanoma cell lines. The death re-
ceptors TRAIL-R1 and -R2 were primarily associated with
the Golgi network, whereas the decoy receptors TRAIL-R3
and -R4 were localised predominantly in the nucleus [19,20].
Activation of NF-UB also appeared to have an important role
in determining the susceptibility of certain melanoma to
TRAIL induced apoptosis [21].
In the present studies we have attempted to examine more
closely the basis of resistance to TRAIL induced apoptosis in
normal cells. We show that the expression and location of
TRAIL-Rs varies in di¡erent types of normal cells and that
decoy receptor expression appears important in protection
against TRAIL induced apoptosis in endothelial cells but
not in melanocytes and ¢broblasts.
2. Materials and methods
Human lung ¢broblasts MRC-5 were obtained from Bio Whittaker
Inc. (Walkersville, MD, USA) and were cultured in Dulbecco’s modi-
¢ed Eagle’s medium containing 5% foetal calf serum (FCS; Common-
wealth Serum Laboratories, Melbourne, Vic., Australia). Melanocytes
were purchased from Clonetics (Walkersville, MD, USA) and cultured
in medium supplied by Clonetics (Edward Kellar, Vic., Australia).
Human umbilical vein endothelial cells (HUVECs) were kindly sup-
plied by D. Clark (Transplantation Unit, John Hunter Hospital, Aus-
tralia). HUVECs were isolated from umbilical veins of placenta by
digestion in collagenase, as described elsewhere [22], and grown in
M199 medium (Gibco, Australia) supplemented with 100 mg/l L-glu-
tamine (Life Technologies), 20% FCS, 135 mg/l heparin (Sigma) and
16.7 Wg/l endothelial cell growth supplement (Sigma). Over 95% of the
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cells expressed CD31 and Von Willebrand factor tested by £ow cyto-
metry.
2.1. Monoclonal antibodies (mAbs) and recombinant proteins
Recombinant human TRAIL (lot 6321-19) prepared as described
elsewhere [1] was supplied by Immunex (Seattle, WA, USA). Re-
combinant human Fas ligand (FasL) was kindly supplied as sterile
supernatant by Immunex. The mAbs against TRAIL-R1 (IgG2a,
M217), TRAIL-R2 (IgG1, M413), TRAIL-R3 (IgG1, M430) and
TRAIL-R4 (IgG1, M444) were also supplied by Immunex [23]. Rab-
bit mAb against the active form of caspase-3 was purchased from
Pharmingen (San Diego, CA, USA). Isotype control mAbs used
were the ID4.5 (mouse IgG2a) mAb against Salmonella typhi supplied
by Dr L. Ashman (IMVS, S.A., Australia), the 107.3 mouse IgG1
mAb purchased from Pharmingen (San Diego, CA, USA) and rabbit
IgG from Sigma. The Golgi was identi¢ed with rhodamine labeled
Fig. 1. Flow cytometric analysis of TRAIL-R expression on intact and permeabilised MRC-5 ¢broblasts (A), HUVECs (B) and melanocytes
(C) without exposure to TRAIL (solid lines) or pretreated with TRAIL (200 ng/ml) at 37‡C for 30 min (dotted lines). The ¢lled histograms are
isotype controls.
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Fig. 2. A: Co-localisation of TRAIL-R2 (A) with the Golgi apparatus (B). The panels under C indicate appearance of merged images. The ap-
pearance of TRAIL-R1 in MRC-5 and HUVECs was identical to that of TRAIL-R2. B: The nuclear localisation of TRAIL-R3 in MRC-5 ¢-
broblasts and the cytoplasmic localisation of TRAIL-R3 in HUVECs. The localisation of TRAIL-R4 in MRC-5 is identical to that of TRAIL-
R3.
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wheat germ agglutinin (WGA lectin) (Sigma) and the nucleus was
identi¢ed by propidium iodide (Sigma).
2.2. Immuno£uorescence and confocal microscopy
Cells were seeded onto gelatine coated sterile glass coverslips in 24
well plates (Becton Dickinson, N.S.W., Australia) 16^24 h before
¢xation. Cells were then stained and examined exactly as described
elsewhere [20].
2.3. Flow cytometry and measurement of apoptosis
Studies on intact and permeabilised cells were similar to the meth-
ods described elsewhere [19,24]. Melanoma cell lines Me10538 and
Me4405 were used as the negative and positive control, respectively
[19]. Apoptotic cells were determined by the propidium iodide method
described elsewhere [25].
2.4. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts of the cells were prepared as described elsewhere
[20]. 3 Wg of each extract was incubated with 2 Wl of gel shift binding
bu¡er (Promega, N.S.W., Australia) for 10 min at room temperature
and then exposed at room temperature for 30 min to double stranded
oligonucleotides for the consensus binding sites of NF-UB (5P-AGTT-
GAGGGGACTTTCCCAGGC-3P) that had been labelled with
[32P]ATP (Amersham, Buckinghamshire, UK) by polynucleotide ki-
nase (Promega). Protein^oligo complexes were separated on a non-
denaturing 6% polyacrylamide gel electrophoresis in 0.5UTBE. Gels
were dried and exposed to an X-ray ¢lm (Hyper¢lm, Amersham).
3. Results
3.1. TRAIL-R expression on MRC-5 ¢broblasts, HUVECs and
melanocytes
Analysis of TRAIL-R expression on intact and permeabi-
lised cells from cultures of MRC-5 ¢broblasts, HUVECs and
melanocytes is shown in Fig. 1A^C. MRC-5 ¢broblasts ex-
pressed TRAIL-R2 but negligible amounts of the other recep-
tors on their surface. Small quantities of the other receptors
were however detected within the cells in studies on permea-
bilised cells. In contrast, HUVECs expressed TRAIL-R1, -R2
and -R3 on the cell surface and within the cells but had negli-
gible expression of TRAIL-R4 on both intact and permeabi-
lised cells. Melanocytes expressed only a small amount of
TRAIL-R2 on their surface, whereas higher levels of this re-
ceptor and marginal amounts of TRAIL-R1 and -R3 were
seen in permeabilised cells. Melanocytes showed no expression
of TRAIL-4 on either intact or permeabilised cells.
Fig. 1 also illustrates regulation of surface TRAIL receptor
expression after interaction with TRAIL. TRAIL induced
marked downregulation of surface expression of death recep-
tors, e.g. TRAIL-R1 on HUVECs and TRAIL-R2 on all
three lines. The surface expression of decoy receptors, in par-
ticular TRAIL-R3 on HUVECs, remained unaltered. Studies
on permeabilised cells suggested that changes induced by
TRAIL were due to relocation of the receptors into the cells
as total expression in permeabilised cells remained stable. This
was con¢rmed by studies using cycloheximide (CHX, 100
Wg/ml) to block protein synthesis and actinomycin D (Act-D,
3 Wg/ml) to block transcription in that neither CHX nor
Act-D treatment a¡ected changes in expression of TRAIL-Rs
(data not shown), which suggested that regulation of
TRAIL-R expression by TRAIL is a posttranslational process.
3.2. Subcellular localisation of the receptors by confocal
microscopy
Higher expression of TRAIL-Rs in permeabilised cells sug-
gested that intracellular pools of these proteins may exist in
normal cells as in melanoma cells [20]. The confocal images in
Fig. 2 illustrate the localisation of the TRAIL-Rs. Death re-
ceptors, TRAIL-R1 in MRC-5 ¢broblasts and HUVECs, and
TRAIL-2 in all three cell lines, were predominantly co-local-
ised with the Golgi apparatus that was identi¢ed with WGA
lectin (Fig. 2A). The localisation of TRAIL-R3 and -R4 var-
ied however between the di¡erent cell types. In MRC-5 ¢bro-
blasts, staining with mAbs against TRAIL-R3 and -R4
showed co-localisation with the nucleus that was identi¢ed
with propidium iodide. The expression was di¡use throughout
the nucleoplasm (Fig. 2B). In contrast, staining of HUVECs
for TRAIL-R3 displayed a sparse punctate cytoplasmic pat-
tern (Fig. 2B). There was no apparent co-localisation of
TRAIL-R3 and -R4 with the Golgi apparatus, the endoplas-
mic reticulum (ER) or the mitochondrion in HUVECs (data
not shown). Melanocytes expressed virtually no TRAIL-R3
and -R4 that could be detected by confocal microscopy.
3.3. TRAIL-R3 protects HUVECs from TRAIL induced
apoptosis
Apoptosis induced by TRAIL, FasL and TNF-K is shown
in Fig. 3A. As expected, none of the normal cells were sensi-
tive to apoptosis induced by these TNF family members. In
the case of FasL and TNF-K this could be accounted for by
Fig. 3. A: Apoptosis induced by TNF-K, FasL and TRAIL. Cells
were treated with TNF-K (100 ng/ml), FasL (1/200) or TRAIL (200
ng/ml) at 37‡C for 18 h before measurement of apoptosis. Jurkat T
cells were used as a positive control. B: Removal of TRAIL-R3
from the cell surface sensitised HUVECs to TRAIL induced apo-
ptosis. HUVECs treated with PI-PLC (1 WM) at 37‡C for 1 h were
either subject to £ow cytometric analysis for surface TRAIL-R3 ex-
pression or exposed to TRAIL (200 ng/ml) in the presence of PI-
PLC for 18 h followed by measurement of apoptosis. Data shown
were mean þ S.E.M. of three individual experiment.
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lack of the corresponding death receptors, Fas and TNFR1,
on the cell surface (data not shown). Low surface expression
of the death receptors for TRAIL may also be responsible, at
least in part, for the resistance of melanocytes to TRAIL
induced apoptosis. TRAIL-R3 was shown in previous studies
to be a GPI anchored protein on the cell membrane [9]. Pre-
treatment of HUVECs with recombinant phosphatidylinositol
speci¢c phospholipase C (PI-PLC) depleted the cell surface of
TRAIL-R3 and sensitised the cells to TRAIL induced apo-
ptosis [9]. A similar experiment is shown in Fig. 3B and con-
¢rms the central role that this receptor plays in resistance of
HUVECs to TRAIL induced apoptosis. Treatment of MRC-5
¢broblasts and melanocytes with PI-PLC however did not
result in an increase in sensitivity of cells to TRAIL induced
apoptosis (data not shown).
3.4. NF-UB is not activated by TRAIL in ¢broblasts and
HUVECs
In previous studies on melanoma lines we found that acti-
vation of NF-UB appeared to mediate resistance of some mel-
anomas to TRAIL induced apoptosis [21]. To study whether
TRAIL induces NF-UB activation in normal cells and thus
protects cells from TRAIL induced apoptosis, nuclear extracts
from TRAIL treated and non-treated MRC-5 ¢broblasts and
HUVECs were subjected to EMSA. Fig. 4 shows that treat-
ment with TRAIL did not result in an increase in basal NF-
UB activation in MRC-5 ¢broblasts or HUVECs, even though
TRAIL-R1 and -R2 were expressed on the cell surface of both
types of cells (Fig. 1A,B), which are known to be capable of
inducing NF-UB activation upon ligation [4,9].
3.5. Expression of FLICE inhibitory protein (c-FLIP) and
inhibitors of apoptosis protein (c-IAP) family members in
cultured normal cells
Intracellular inhibitors of apoptosis c-FLIP and c-IAPs
have been suggested to play an important role in resistance
of cells to apoptosis. We therefore examined expression of c-
FLIP and c-IAP family members, c-IAP1, c-IAP2 and XIAP,
in permeabilised MRC-5 ¢broblasts, HUVECs and melano-
cytes. Fig. 5A demonstrates that only a negligible amount of
c-FLIP was detected in MRC-5 and HUVECs and none in
melanocytes. In contrast, all three lines expressed relatively
high levels of all the IAP family members tested (Fig. 5B).
3.6. Exposure of MRC-5 ¢broblasts to TRAIL activates
caspase-3
Activation of caspase-3 is thought to be the ‘point of no
return’ in apoptotic signal transduction [26,27]. We examined
whether the failure of TRAIL to induce apoptosis in normal
cells takes place upstream of caspase-3 by measuring the acti-
vation status of caspase-3 in the cells with a mAb that specif-
Fig. 5. Flow cytometric analysis of expression (thin lines) of c-FLIP (A) and IAP family members (B) in permeabilised MRC-5 ¢broblasts,
HUVECs and melanocytes. The thick lines are isotype controls.
Fig. 4. NF-UB activation status analysed by EMSA. Nuclear ex-
tracts from MRC-5 ¢broblasts and HUVECs before and after
TRAIL treatment (200 ng/ml) at 37‡C for 30 min were subject to
EMSA.
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ically recognises the active form of caspase-3. Activated cas-
pase-3 was readily detected in MRC-5 ¢broblasts but not in
HUVECs and melanocytes upon TRAIL treatment at levels
comparable to that seen in the TRAIL sensitive Jurkat T cell
line (Fig. 6A). The kinetics of caspase-3 activation in MRC-5
¢broblasts and Jurkat T cells is shown in Fig. 6B and indi-
cates that activated caspase-3 was detectable as early as 30
min after TRAIL treatment in MRC-5 ¢broblasts and peaked
at 4 h to the level seen in Jurkat T cells.
4. Discussion
The results described above suggest that expression and
intracellular distribution of TRAIL-Rs in normal cells vary
between cells from di¡erent tissues. In HUVECs the two
death receptors, TRAIL-R1 and -R2, and the decoy receptor,
TRAIL-R3, are expressed on the surface whereas in melano-
cytes and ¢broblasts only the death receptor, TRAIL-R2, was
detected on the cell surface. Studies on permeabilised cells
show that all receptors except TRAIL-R4 are expressed with-
in the cells to varying degrees. TRAIL-R4 was only weakly
detected or absent in the cells. Exposure to TRAIL resulted in
marked downregulation of the surface death receptors but
had little e¡ect on the decoy receptors in the three types of
cells. These results are similar to those found in studies on
melanoma cell lines [19,20] and are consistent with PCR anal-
ysis of mRNAs for TRAIL-Rs in normal cells [1,3,5].
Co-localisation studies indicated that TRAIL-R1 and -R2
in all three cell lines are predominantly located in the Golgi
network and on the cell surface. These results are similar to
our previous studies in melanoma cell lines [20] and to studies
on TNFR1 and Fas expression [28,29]. Taken together, these
¢ndings suggest that localisation in the Golgi apparatus may
be a common feature of TNF receptor family members induc-
ing apoptosis. In contrast, the intracellular location of the
decoy receptors, TRAIL-R3 and -R4, was found to vary in
cells from di¡erent tissues. In HUVECs, TRAIL-R3 was ex-
pressed in the cytoplasm with a punctate staining pattern,
suggesting the location of this receptor in cytoplasmic organ-
elle(s). The organelle(s) involved are not yet known but are
not Golgi, ER or mitochondria. In contrast, TRAIL-R3 in
MRC-5 ¢broblasts was found to be localised in the nucleus.
This is consistent with our previous studies on human mela-
noma cell lines [19,20]. The basis for and signi¢cance of the
nuclear localisation of TRAIL-R3 is currently unknown, but
it is of interest that TRAIL-R3 has sequences compatible with
those needed to bind to the nuclear export factor exportin 1.
[30,31].
Even though the intracellular location and surface expres-
sion of TRAIL-Rs varied between di¡erent tissues, all were
resistant to TRAIL induced apoptosis. In melanocytes, only a
small amount of the death receptor TRAIL-R2 was detected
on the cell surface and this could account for their resistance
to TRAIL induced apoptosis. This is because we have shown
previously that there was a direct correlation between the level
of surface death receptor expression and TRAIL induced
apoptosis [19].
In the case of HUVECs, TRAIL-R3 expression was clearly
needed for resistance to TRAIL induced apoptosis in that, as
reported by others, removal of the receptor resulted in sensi-
tivity to TRAIL induced apoptosis [9]. These observations
suggest that TRAIL-R3, when expressed on the cell surface
at high levels relative to death receptors, may protect cells
from TRAIL induced apoptosis. It was notable that
TRAIL-R3 in HUVECs was localised in the cytoplasmic or-
ganelle(s), whereas TRAIL-R3 in MRC-5 ¢broblasts was
found to be predominantly localised within the nucleus. This
suggests that posttranslational mechanisms that direct the
newly synthesised protein to di¡erent compartments of the
cells may play a critical role in determining whether the decoy
receptors may be deployed on the cell surface and thus protect
cells from TRAIL induced apoptosis.
MRC-5 ¢broblasts expressed high levels of the death recep-
tor TRAIL-R2 but only negligible amounts of the decoy re-
ceptor TRAIL-R3 on the surface, yet were not sensitive to
TRAIL induced apoptosis. In studies on melanoma cells we
found that resistance to TRAIL induced apoptosis was depen-
dent in part on activation of NF-UB [21]. The latter however
did not appear to be involved in resistance of normal cells to
TRAIL induced apoptosis in that we were unable to show
activation of NF-UB by TRAIL in EMSA of MRC-5 ¢bro-
blasts and HUVECs.
We also examined whether the cells may contain inhibitors
of TRAIL induced apoptosis such as c-FLIP [32,33]. How-
ever, the latter was only detected at negligible levels in the
cells and was therefore unlikely to account for the resistance
to TRAIL induced apoptosis. This is consistent with our pre-
vious ¢ndings in melanoma cells [19]. The IAP family mem-
bers c-IAP1, c-IAP2 and XIAP were expressed at high levels
in the normal cells and are known to inhibit activation of
caspase-9, -3, and -7 [16,17]. It appears unlikely however
Fig. 6. A: Flow cytometric analysis of activated caspase-3 in MRC-
5 ¢broblasts and Jurkat T cells treated with TRAIL (200 ng/ml) at
37‡C for 4 h before ¢xation. The ¢lled histograms are isotype con-
trols. B: Kinetics of caspase-3 activation induced by TRAIL. Cells
were treated with TRAIL (200 ng/ml) at 37‡C for the indicated peri-
ods before ¢xation. Activated caspase-3 was measured by £ow cyto-
metry. Data shown are percentage of activated caspase-3 positive
cells.
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that these proteins were responsible for protection against
TRAIL induced apoptosis of MRC-5 ¢broblasts as activated
caspase-3 was detected at high levels in MRC-5 ¢broblasts
after exposure to TRAIL. It therefore appears that mecha-
nisms downstream of activated caspase-3 were involved in
resistance of MRC-5 ¢broblasts to TRAIL induced apoptosis.
In summary, our results indicate that TRAIL decoy recep-
tor expression is not the only mechanism involved in protec-
tion of normal cells against TRAIL induced apoptosis. Low
surface death receptor expression and inhibitory mechanisms
downstream of activated caspase-3 appear to be additional
mechanisms in protection of melanocytes and ¢broblasts re-
spectively.
Acknowledgements: This work was supported by the Melanoma and
Skin Cancer Research Institute, Sydney, Australia and N.S.W. State
Cancer Council. We would like to thank the Electron Microscope
Unit, University of Sydney, for use of their confocal microscope.
We also wish to thank Professor A.D. Hibberd and Mr D. Clark in
the Transplantation Unit, John Hunter Hospital for supply of HU-
VECs.
References
[1] Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang,
C.-P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C.,
Smith, C.A. and Goodwin, R.G. (1995) Immunity 3, 673^682.
[2] Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore,
A. and Ashkenazi, A. (1996) J. Biol. Chem. 271, 12687^12690.
[3] Pan, G., O’Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R.,
Ni, J. and Dixit, V.M. (1997) Science 276, 111^113.
[4] Schneider, P., Thome, M., Burns, K., Bodmer, J.L., Hofmann,
K., Kataoka, T., Holler, N. and Tschopp, J. (1997) Immunity 7,
831^836.
[5] Pan, G., Ni, J., Wei, Y.-F., Yu, G., Gentz, R. and Dixit, V.M.
(1997) Science 277, 815^818.
[6] Walczak, H., Degli-Esposti, M.A., Johnson, R.S., Smolak, P.J.,
Waugh, J.Y., Boiani, N., Timour, M.S., Gerhart, M.J., Schooley,
K.A., Smith, C.A., Goodwin, R.G. and Rauch, C.T. (1997)
EMBO J. 16, 5386^5397.
[7] Screaton, G.R., Mongkolsapaya, J., Xu, X.-N., Cowper, A.E.,
McMichael, A.J. and Bell, J.I. (1997) Curr. Biol. 7, 693^696.
[8] Degli-Esposti, M.A., Smolak, P.J., Walczak, H., Waugh, J.,
Huang, C.-P., DuBose, R.F., Goodwin, R.G. and Smith, C.A.
(1997) J. Exp. Med. 186, 1165^1170.
[9] Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Sku-
batch, M., Baldwin, D., Ramakrishnan, L., Gray, C.L., Baker,
K., Wood, W.I., Goddard, A.D., Godowski, P. and Ashkenazi,
A. (1997) Science 277, 818^821.
[10] Mongkolsapaya, J., Cowper, A.E., Xu, X.N., Morris, G., McMi-
chael, A.J., Bell, J.I. and Screaton, G.R. (1998) J. Immunol. 160,
3^6.
[11] Schneider, P., Bodmer, J.L., Thome, M., Hofmann, K., Holler,
N. and Tschopp, J. (1997) FEBS Lett. 416, 329^334.
[12] Pan, G., Ni, J., Yu, G., Wei, Y.F. and Dixit, V.M. (1998) FEBS
Lett. 424, 41^45.
[13] Marsters, S.A., Sheridan, J.P., Pitti, R.M., Huang, A., Skubatch,
M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A.D., God-
owski, P. and Ashkenazi, A. (1997) Curr. Biol. 7, 1003^1006.
[14] Degli-Esposti, M.A., Dougall, W.C., Smolak, P.J., Waugh, J.Y.,
Smith, C.A. and Goodwin, R.G. (1997) Immunity 7, 813^820.
[15] Gri⁄th, T.S. and Lynch, D.H. (1998) Curr. Opin. Immunol. 10,
559^563.
[16] Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev. 13, 239^252.
[17] Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V. and
Baldwin Jr., A.S. (1998) Science 281, 1680^1683.
[18] Emery, J.G., McDonnell, P., Burke, M.B., Deen, K.C., Lyn, S.,
Silverman, C., Dul, E., Appelbaum, E.R., Eichman, C., DiPrin-
zio, R., Dodds, R.A., James, I.E., Rosenberg, M., Lee, J.C. and
Young, P.R. (1998) J. Biol. Chem. 273, 14363^14367.
[19] Zhang, X.D., Franco, A., Myers, K., Gray, C., Nguyen, T. and
Hersey, P. (1999) Cancer Res. 59, 2747^2753.
[20] Zhang, X.D., Franco, A., Gray, C., Nguyen, T. and Hersey, P.
(2000) J. Immunol. 164, 3961^3970.
[21] Franco, A., Zhang, X.D., Van Berkel, E., Thomas, W., Nguyen,
T. and Hersey, P. (2000) J. Immunol. (submitted).
[22] Ja¡e, E.A., Nachman, R.L., Becker, C.G. and Minick, C.R.
(1973) J. Clin. Invest. 52, 2745^2756.
[23] Gri⁄th, T.S., Rauch, C., Smolak, P.J., Waugh, J.Y., Boiani, N.,
Lynch, D.H., Smith, C.A., Goodwin, R.G. and Kubin, M.Z.
(1999) J. Immunol. 162, 2597^2605.
[24] Jung, T., Schauer, U., Heusser, C., Neumann, C. and Rieger, C.
(1993) J. Immunol. Methods 159, 197^207.
[25] Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. and
Riccardi, C. (1991) J. Immunol. Methods 139, 271^279.
[26] Cohen, G.M. (1997) Biochem. J. 15, 1^16.
[27] Samejima, K., Tone, S., Kottke, T.J., Enari, M., Sakahira, H.,
Cooke, C.A., Durrieu, F., Martins, L.M., Nagata, Kaufmann,
S.H. and Earnshaw, W.C. (1998) J. Cell Biol. 143, 225^239.
[28] Jones, S.J., Ledgerwood, E.C., Prins, J.B., Galbraith, J., John-
son, D.R., Pober, J.S. and Bradley, J.R. (1999) J. Immunol. 162,
1042^1049.
[29] Bennett, M., Macdonald, K., Chan, S.-W., Luzio, J.P., Simari,
R. and Weissberg, P. (1998) Science 282, 290^293.
[30] Ullman, K.S., Powers, M.A. and Forbes, D.J. (1997) Cell 90,
967^970.
[31] Stade, K., Ford, C.S., Guthrie, C. and Weis, K. (1997) Cell 90,
1041^1050.
[32] Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K.,
Steiner, V., Bodmer, J.L., Schroter, M., Burns, K., Mattmann,
C., Rimoldi, D., French, L.E. and Tschopp, J. (1997) Nature 388,
190.
[33] Gri⁄th, T.S., Chin, W.A., Jackson, G.C. and Lynch, D.H.
(1998) J. Immunol. 161, 2833^2840.
FEBS 24152 29-9-00 Cyaan Magenta Geel Zwart
X.D. Zhang et al./FEBS Letters 482 (2000) 193^199 199
